Agenus Inc
AGEN
Market Cap$3.72B
Close$
$-5.86
217.9% downside
Current Fair Value
217.9% downsideOvervalued by 217.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.72 Billion |
|---|---|
| Enterprise Value | $3.65 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.69 |
| Beta | 1.31 |
| Outstanding Shares | 418,920,071 |
| Avg 30 Day Volume | 479,121 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -15.11 |
|---|---|
| PEG | 43.33 |
| Price to Sales | - |
| Price to Book Ratio | -4.97 |
| Enterprise Value to Revenue | 23.37 |
| Enterprise Value to EBIT | -22.81 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.08 |
Revenue Sources
No data
ESG Score
No data
About Agenus Inc
CEO: Garo Armen Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators , pa...